Epidermolysis hyperkeratosis (EH) is a rare skin disorder characterized by blistering, redness, and inflammation of the skin. It is caused by mutations in the genes responsible for the formation of the protein keratin, which makes up the outermost layer of the skin. Although the exact cause of EH is unknown, it is thought to be an inherited disorder. The symptoms of EH can range from mild to severe, and can affect individuals of any age. While treatments are available to manage the symptoms, there is currently no known cure for the disorder.
Epidermolysis hyperkeratosis (EH) is a rare skin disorder in which the skin becomes fragile and easily damaged. It is caused by mutations in the genes responsible for the formation of the protein keratin, which makes up the outermost layer of the skin. These mutations cause the skin to become extremely fragile and prone to blistering and inflammation. EH can affect individuals of any age, and the severity of the disorder can vary from mild to severe. Common symptoms of EH include redness, blistering, and inflammation of the skin. In some cases, the skin may also become thickened and form calluses.
Diagnosis of EH is typically made through a physical exam and a review of the patient’s medical history. In some cases, a biopsy may be performed to confirm the diagnosis. Treatment of EH is typically focused on managing the symptoms and preventing further damage to the skin. This may include the use of moisturizers, topical corticosteroids, or other medications to reduce inflammation and blistering. In some cases, surgery may be necessary to remove thickened skin or to repair damaged tissue.
Although there is currently no known cure for EH, researchers are actively working to develop new treatments and therapies. The development of gene therapy, stem cell therapy, and other treatments are currently being explored as potential treatments for EH. In addition, researchers are working to better understand the genetic basis of EH. By identifying the specific genes responsible for the disorder, researchers hope to develop new treatments that can target the underlying cause of the disorder.
Epidermolysis hyperkeratosis is a rare skin disorder that can cause blistering, redness, and inflammation of the skin. Although there is currently no known cure for the disorder, treatments are available to manage the symptoms and prevent further damage to the skin. Researchers are actively working to develop new treatments and therapies for EH, and to better understand the genetic basis of the disorder. With continued research, it is hoped that a cure for EH will one day be discovered.
1.
There has been a recent decrease in the risk of a recurrence of colorectal cancer in stage I to III cases.
2.
In NSCLC, subcutaneous Lazertinib + Amivantamab Dosing Is Not Worse Than IV Dosing.
3.
Recurrent UTIs impact eGFR in children with vesicoureteral reflux
4.
Month-Long Wait Times Caused by US Physician Shortage.
5.
Pharyngoesophageal junction cancer is not a good candidate for endoscopically assisted transoral surgery.
1.
A Closer Look at Poorly Differentiated Carcinoma: Uncovering its Complexities
2.
The Importance of Early Detection in Angiosarcoma: A Story of Survival
3.
Leukemia in Focus: Tools, Trials, and Therapy Strategies for Modern Medical Practice
4.
New Research Advances in the Treatment of Multiple Myeloma and Plasmacytoma
5.
Managing KRAS Inhibitor Toxicities: Focus on Rash and Beyond
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Incidence of Lung Cancer- An Overview to Understand ALK Rearranged NSCLC
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part III
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part III
4.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion IV
5.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part V
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation